Royalty Pharma Plc (RPRX) Institutional Ownership Changes & 13F Activity

Royalty Pharma Plc (RPRX) institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC 13F filings (Q1 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions among tracked filers. Notable filers include Renaissance Technologies LLC, Torray Fund, Dorsey Asset Management, Sequoia Financial Advisors, and Viking Global Investors.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q2 2023Renaissance Technologies LLCSell-530,200770,700$23,691
Q2 2023Torray FundBuy276,643413,815$12,720,673
Q1 2023Viking Global InvestorsBuy1,195,73811,204,249$403,689,091
Q1 2023Renaissance Technologies LLCBuy431,9001,300,900$46,871
Q1 2023Torray FundSell-199137,172$4,942,307
Q4 2022Viking Global InvestorsSell-873,08310,008,511$395,536,355
Q4 2022Renaissance Technologies LLCBuy685,100869,000$34,343
Q4 2022Torray FundSell-1,653137,371$5,428,902
Q3 2022Viking Global InvestorsSell-1,489,10010,881,594$437,222
Q3 2022Torray FundBuy12139,024$5,586
Q2 2022Viking Global InvestorsBuy1,606,22212,370,694$520,064
Q2 2022Torray FundBuy6,942139,012$5,844
Q1 2022Berkshire HathawaySell-7,151,8961,496,372$58,299
Q1 2022Renaissance Technologies LLCSell-615,200183,900$7,165
Q1 2022Viking Global InvestorsBuy449,09410,764,472$419,384
Q1 2022Torray FundSell-5,871132,070$5,145
Q4 2021Viking Global InvestorsBuy6,174,87010,315,378$411,068
Q4 2021Berkshire HathawaySell-4,497,6348,648,268$344,633
Q4 2021Torray FundBuy137,941137,941$5,497
Q4 2021Renaissance Technologies LLCBuy15,500799,100$31,844
Q3 2021Berkshire HathawayBuy13,145,90213,145,902$475,093
Q3 2021Viking Global InvestorsBuy901,8544,140,508$149,638
Q3 2021Renaissance Technologies LLCSell-45,000783,600$28,319
Q2 2021Viking Global InvestorsBuy1,176,9013,238,654$132,752
Q2 2021Renaissance Technologies LLCBuy828,600828,600$33,964
Q1 2021Viking Global InvestorsSell-225,2472,061,753$89,934
Q4 2020Viking Global InvestorsBuy338,9362,287,000$114,464
Q3 2020Viking Global InvestorsSell-566,9211,948,064$81,955
Q2 2020Viking Global InvestorsBuy2,514,9852,514,985$122,103

Frequently asked questions about RPRX activity

  • Which institutional owners are buying RPRX?

    Institutional owners buying RPRX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in RPRX activity?

    "Buy" means an investor increased their reported position in RPRX compared to the prior reporting period. This reflects growing exposure to Royalty Pharma Plc (RPRX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in RPRX increasing?

    Institutional interest in RPRX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.

Related RPRX insights